Generic pharmaceutical company focused on women's health, cardiology and vaccines, sold domestically and exported.
Generic pharmaceutical company focused on women's health, cardiology and vaccines, sold domestically and exported.
Sells branded generics, off-patent drugs marketed under its own names, mostly in India, where doctors' prescriptions and a large field sales force drive demand; it also sells abroad. Listed in 2024, it has had Bain Capital as an investor, and runs a vaccine subsidiary, Gennova.
In one line: A women's-health-focused Indian generics maker.
Moat: narrow (brand, distribution). Established prescriber relationships in women's health, a therapy area with fewer large competitors.
Headquarters: Pune, India · Founded: 1981 · Employees: 6,914
Size Emcure Pharmaceuticals (EMCURE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $4.74B, the 219th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,335 on 18 Nov 2026.
Performance Over six months the shares gained 36.5%, against +5.6% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 21.1% over the last twelve months (peer median +9.5%); the operating margin is 15.6% (peer median 17.1%).
Valuation It trades at 33.6× forward earnings against a peer median of 21.5× (5th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.8 points above its cost of capital (9.4% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹102B | ₹91.3B | ₹78.2B | ₹65.9B | ₹59.4B |
| Revenue growth | — | +17% | +19% | +11% | — |
| Gross profit | ₹40.0B | ₹29.2B | ₹23.5B | ₹21.1B | ₹19.3B |
| EBITDA | ₹20.3B | ₹17.2B | ₹14.0B | ₹11.8B | ₹11.5B |
| Net income | ₹10.9B | ₹9.24B | ₹6.81B | ₹4.98B | ₹5.32B |
| Free cash flow | n/a | ₹4.90B | ₹5.24B | ₹6.31B | ₹1.83B |
| Capital expenditure | n/a | ₹5.48B | ₹4.07B | ₹3.07B | ₹4.03B |
| Total debt | ₹17.6B | ₹15.2B | ₹10.2B | ₹23.2B | ₹23.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals EMCURE.NS | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMCURE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +32.2% | -1.3% | 2nd highest of 21 |
| 6-month return | +36.5% | +5.6% | highest of 21 |
| Distance from 52-week high | -3.9% | -33.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +21.1% | +9.5% | 6th highest of 19 |
| Operating margin | 15.6% | 17.1% | 9th lowest of 19 |
| Forward P/E | 33.6× | 21.5× | 5th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 15.9% | 3.4% | 5th most demanding of 17 |
| Growth delivered (Del g) | +12.7% | +10.9% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | +3.2 pp | -6.3 pp | 5th most demanding of 17 |
| ROIC minus cost of capital | +7.8 pp | +3.4 pp | 6th highest of 17 |
| EV / EBITDA | 22.6× | 18.7× | 5th most expensive of 11 |
| Net debt / EBITDA | 0.8× | -0.8× | 3rd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |